Heart Failure (HF) Clinical Trial
— AVANTIOfficial title:
A Multicenter, Randomized, Parallel Group, Double Blind, Active and Placebo Controlled Study of BAY1753011, a Dual V1a/V2 Vasopressin Receptor Antagonist, in Patients With Congestive Heart Failure: AVANTI Study
Verified date | April 2022 |
Source | Bayer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To assess the efficacy of 30 mg of BAY1753011, with or without furosemide, versus furosemide alone in patients with heart failure and objective evidence of congestion.
Status | Completed |
Enrollment | 482 |
Est. completion date | May 21, 2021 |
Est. primary completion date | April 16, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: - History of CHF on individually optimized treatment with HF medications unless contraindicated or not tolerated, for at least 12 weeks prior to index hospitalization and in accordance with international guidelines. - Subjects admitted to the hospital with a primary diagnosis of decompensated HF including symptoms and signs of fluid overload requiring IV diuretic therapy in the Emergency room (ER) or any time between day 1-3 of hospital admission (index hospitalization). - Subjects on an average/usual total daily dose of loop diuretic = 40 mg of furosemide or equivalent, within 4 weeks prior to index hospitalization. - At least one of the following 5 parameters any day between 3-7 of index hospitalization (screening period) - Natriuretic peptides Brain natriuretic peptide/N-terminal prohormone of brain natriuretic peptide (BNP/NT-proBNP): - Drop in BNP or NT-proBNP = 30% from admission values (if measured during index hospitalization) or - BNP = 500 pg/ml or NT-proBNP = 1800 pg/ml at screening (day 3 to 7 of index hospitalization) - Body weight (BW) loss <0.4 kg per 40 mg furosemide at day 4 of index hospitalization - Composite congestion score (CCS) = 3 - Hypervolemic hyponatremia defined as serum sodium < 136 mmol/l - In hospital worsening renal function defined as increased serum creatinine = 0.3 mg/dl compared to index hospitalization admission values AND at least one the following - Jugular venous pressure (JVP) = 10 cm on physical examination - Inferior vena cava (IVC) diameter > 21 mm - IVC collapse with sniff < 50% - At least 2+ peripheral edema or pulmonary edema or pleural effusion on chest X-ray or clinical exam Exclusion Criteria - Active or history of acute inflammatory heart disease, within 3 months prior to screening, e.g., acute myocarditis - Acute coronary syndrome, including unstable angina, Non-ST segment elevation myocardial infarction (NSTEMI) or ST segment elevation myocardial infarction (STEMI), or major Cardiovascular (CV) surgery including coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI) within 3 months prior to screening - Any primary cause of HF scheduled for surgery or interventional therapy (e.g., TAVI), e.g., valve disease such as severe aortic stenosis or mitral valve regurgitation - Requirement of mechanical support (intra-aortic balloon pump, endotracheal intubation, mechanical ventilation, or any ventricular assist device) or ultrafiltration/hemodialysis - Estimated glomerular filtration rate of < 30 ml/min/1.73 m*2 determined by the Modified Diet and Renal Disease equation at screening; reassessments allowed as clinically needed - Serum potassium = 5.5 mmol/L or = 3.3 mmol/L at screening; reassessments allowed as clinically needed - Serum sodium = 146 mmol/L or = 130 mmol/L at screening; reassessments allowed as clinically needed - Concomitant treatment with potassium-sparing diuretic (with the exception of mineralocorticoid- receptor antagonist (MRA) that cannot be stopped prior to randomization and for the duration of the treatment period. |
Country | Name | City | State |
---|---|---|---|
Austria | Krankenhaus St. Josef Braunau | Braunau | Oberösterreich |
Austria | Medizinische Universität Graz | Graz | Steiermark |
Austria | Universitätsklinikum St. Pölten | St. Pölten | Niederösterreich |
Austria | Klinik Floridsdorf - Krankenhaus Nord | Wien | |
Austria | Universitätsklinikum AKH Wien | Wien | |
Bulgaria | MHAT Haskovo | Haskovo | |
Bulgaria | Spec Hosp for Active Treatm in Cardiology Sv Georgi Pernik | Pernik | |
Bulgaria | UMHAT Dr. Georgi Stranski | Pleven | |
Bulgaria | Multiprofile Hospital for Active Treatment Medline Clinic | Plovdiv | |
Bulgaria | MHAT "Knyaginya Klementina - Sofia"EAD | Sofia | |
Bulgaria | NMTH Tzar Boris III | Sofia | |
Bulgaria | UMHAT Tsaritsa Joanna-ISUL EAD Sofia | Sofia | |
Greece | G. GENNIMATAS General State Hospital of Athens | Athens | |
Greece | University General Hospital of Athens "ATTIKON" | Chaidari - Athens | |
Greece | University General Hospital of Ioannina | Ioannina | |
Greece | KAT General Hospital of Athens | Kifisia / Athens | Attica |
Greece | Univ. General Hospital of Larissa | Larissa | |
Greece | Konstantopoulio General Hospital of Nea Ionia - AGIA OLGA | Nea Ionia / Athens | |
Greece | "AHEPA" University General Hospital of Thessaloniki | Thessaloniki | |
Greece | Hippokration General Hospital of Thessaloniki | Thessaloniki | |
Hungary | Budai Irgalmasrendi Korhaz | Budapest | |
Hungary | Magyar Honvedseg Egeszsegugyi Kozpont Honvedkorhaz | Budapest | |
Hungary | University of Semmelweis/ Semmelweis Egyetem | Budapest | |
Hungary | Kanizsai Dorottya Hospital | Nagykanizsa | |
Hungary | Josa Andras Hospital | Nyiregyhaza | |
Hungary | Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz | Szekesfehervar | |
Hungary | Tolna Megyei Balassa Janos Korhaz | Szekszard | |
Hungary | Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz | Szolnok | |
Hungary | Zala Megyei Szent Rafael Korhaz | Zalaegerszeg | |
Israel | Barzilai Medical Center | Ashkelon | |
Israel | Rambam Health Corporation | Haifa | |
Israel | Hadassah Hebrew University Hospital Ein Kerem | Jerusalem | |
Israel | Health Corporation of Galilee Medical Center | Nahariya | |
Israel | Chaim Sheba Medical Center | Ramat Gan | |
Israel | Tel-Aviv Sourasky Medical Center | Tel Aviv | |
Israel | Shamir Medical Center (Assaf Harofeh) | Zrifin | |
Italy | AUSL Toscana Sud-Est | Arezzo | Toscana |
Italy | ASST Papa Giovanni XXIII | Bergamo | Lombardia |
Italy | ASST Spedali Civili di Brescia | Brescia | Lombardia |
Italy | A.O.U. di Ferrara | Ferrara | Emilia-Romagna |
Italy | IRCCS Centro Cardiologico Monzino S.p.A | Milano | Lombardia |
Italy | Fondazione Policlinico di Monza | Monza Brianza | Lombardia |
Italy | Fondazione Toscana Gabriele Monasterio (FTGM) | Pisa | Toscana |
Italy | AUSL della Romagna | Rimini | Emilia-Romagna |
Italy | A.O.U. Senese | Siena | Toscana |
Poland | Uniwersytecki Szpital Kliniczny w Bialymstoku | Bialystok | |
Poland | 10 Wojskowy Szpital Kliniczny z Poliklinika SPZOZ | Bydgoszcz | |
Poland | Szpital sw. Wincentego a Paulo | Gdynia | |
Poland | Samodzielny Publiczny Specjalistyczny Szpital Zachodni | Grodzisk Mazowiecki | |
Poland | Szpital Kliniczny Przemienienia Panskiego | Poznan | |
Poland | Szpital Wojewodzki Nr 2 | Rzeszow | |
Poland | Uniwersyteckie Centrum Kliniczne Warszawskiego UM | Warszawa | |
Poland | Uniwersytecki Szpital Kliniczny UM we Wroclawiu | Wroclaw | |
Portugal | Hospital de Cascais | Alcabideche | Lisboa |
Portugal | CHL - Hospital Santo Andre | Leiria | |
Portugal | CHLO - Hospital Sao Francisco Xavier | Lisboa | |
Portugal | Hospital da Luz - Lisboa | Lisboa | |
Portugal | CHUP - Hospital Santo Antonio | Porto | |
Portugal | CHS - Hospital Sao Bernardo | Setubal | Setúbal |
Spain | Hospital Álvaro Cunqueiro | Babio - Beade | Pontevedra |
Spain | Hospital del Mar | Barcelona | |
Spain | Hospital Ramón y Cajal | Madrid | |
Spain | Hospital Virgen de la Victoria | Málaga | |
Spain | Hospital Clínico Universitario de Valencia | Valencia | |
Spain | Hospital General Universitario de Valencia | Valencia | |
Spain | Hospital Universitari i Politècnic La Fe | Valencia |
Lead Sponsor | Collaborator |
---|---|
Bayer |
Austria, Bulgaria, Greece, Hungary, Israel, Italy, Poland, Portugal, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | PART A: Change in body weight | Compare Day 30 (End of part A) with Day 1 (Start of part A) | ||
Primary | PART A: Change in serum creatinine | Compare Day 30 (End of part A) with Day 1 (Start of part A) | ||
Primary | PART B: Change in body weight | Compare Day 60 (End of part B) with Day 30 (Start of part B) | ||
Primary | PART B: Change in log transformed blood urea nitrogen (BUN)/creatinine ratio | Compare Day 60 (End of part B) with Day 30 (Start of part B) | ||
Secondary | Incidence of Treatment-emergent adverse event (including Serious adverse event) | From the time of first study drug administration up to 7 days after the last dose of study drug (Day 60) | ||
Secondary | Change in augmentation index | Up to 60 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03456856 -
A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.
|
Phase 4 | |
Completed |
NCT02301689 -
SchlaHF-XT-Register. Sleep Disordered Breathing in Heart Failure Register
|
||
Completed |
NCT04915118 -
A Study Called NATION-OS to Learn About the Link Between N-terminal proBNP (NT-proBNP) Levels and Medical Problems Due to Heart Failure (HF) in German Patients With HF
|
||
Completed |
NCT02200822 -
Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients
|
Phase 4 | |
Recruiting |
NCT04149743 -
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
|
N/A | |
Recruiting |
NCT05652218 -
REsynchronization Comparison In LBBB and Normal or Mildly Reduced VENTricular Function With CRT (REINVENT-CRT)
|
N/A | |
Completed |
NCT02127307 -
Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.
|
N/A | |
Completed |
NCT01936649 -
Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.
|
Phase 4 |